SEC Comment Letter 0000000000-24-013820 to Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc.
Date: Dec. 16, 2024 · CIK: 0001907108 · Accession: 0000000000-24-013820
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283781
Letter
December 16, 2024 R. Nolan Townsend Chief Executive Officer Lexeo Therapeutics, Inc. 345 Park Avenue South, Floor 6 New York, NY, 10010 Re:Lexeo Therapeutics, Inc. Registration Statement on Form S-3 Filed December 13, 2024 File No. 333-283781 Dear R. Nolan Townsend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Megan Baier
Show Raw Text
December 16, 2024
R. Nolan Townsend
Chief Executive Officer
Lexeo Therapeutics, Inc.
345 Park Avenue South, Floor 6
New York, NY, 10010
Re:Lexeo Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 13, 2024
File No. 333-283781
Dear R. Nolan Townsend:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Megan Baier